SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM) today announced that its MassARRAY® technology and iPLEX™ assay were used by leading scientists from international research institutions and, in independent studies, significantly advanced the understanding of cancer, diabetes and drug-resistant malaria. Results from several of these studies were published in highly recognized peer-reviewed journals as follows:
